MDGL
Madrigal Pharmaceuticals Inc.
$547.96
+$5.84(+1.08%)
53
Overall
40
Value
66
Tech
--
Quality
Market Cap
$12.70B
Volume
567.23K
52W Range
$265.00 - $577.90
Target Price
$527.75
Company Overview
| Mkt Cap | $12.70B | Price | $547.96 |
| Volume | 567.23K | Change | +1.08% |
| P/E Ratio | -27.2 | Open | $542.85 |
| Revenue | $180.1M | Prev Close | $542.12 |
| Net Income | $-465.9M | 52W Range | $265.00 - $577.90 |
| Div Yield | N/A | Target | $527.75 |
| Overall | 53 | Value | 40 |
| Quality | -- | Technical | 66 |
No chart data available
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
Madrigal Pharmaceuticals (MDGL) Receives a Buy from B. Riley Securities
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Truist Financial
TipRanks Auto-Generated Intelligence Newsdesk•19 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDGL | $547.96 | +1.1% | 567.23K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Madrigal Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW